Jardiance vs Metformin: Switching Between Them (A Women's Guide)

What Are These Two Drugs and How Do They Work Differently?

Metformin and Jardiance both lower blood glucose, but through completely different mechanisms. Metformin reduces glucose production in your liver and improves how your muscle cells respond to insulin. Jardiance tells your kidneys to stop reabsorbing glucose and to flush it out in urine instead. That one difference in mechanism explains most of the practical differences between them in your day-to-day life.

Metformin: The Long-Standing Standard

Metformin has been prescribed since the 1950s in Europe and received FDA approval in 1994. It lowers fasting glucose by suppressing hepatic gluconeogenesis and reduces HbA1c by roughly 1.0 to 1.5 percentage points as monotherapy. It does not cause hypoglycemia on its own. It is weight-neutral to modestly weight-reducing.

For women, metformin has an additional role beyond type 2 diabetes. ACOG supports its use in PCOS to improve menstrual regularity and insulin sensitivity, particularly when lifestyle changes alone are insufficient. That off-label application is firmly embedded in women's reproductive health practice.

Jardiance (Empagliflozin): The Newer Cardio-Kidney Drug

Jardiance received FDA approval for type 2 diabetes in 2014 and works by blocking the SGLT2 transporter in the kidney proximal tubule. This forces roughly 70 grams of glucose per day into urine. The result is a modest HbA1c reduction of 0.5 to 1.0 percentage points, weight loss averaging 2 to 3 kg, and a blood pressure reduction of 3 to 5 mmHg systolic, without insulin involvement.

Its cardiovascular and kidney trial data changed prescribing practice globally. The EMPA-REG OUTCOME trial published in the NEJM (2015) showed a 38% relative reduction in cardiovascular death among adults with type 2 diabetes and established cardiovascular disease. That signal was the first of its kind from a glucose-lowering drug.

How Effective Are They? What the Trials Show

Neither drug has been compared head-to-head in a published randomized trial designed specifically around that comparison. What we have are two landmark trials in different populations, at different eras of diabetes care, with different primary outcomes.

EMPA-REG OUTCOME (Jardiance, 2015)

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily was added to standard care. At a median follow-up of 3.1 years, the trial showed a 38% reduction in cardiovascular death, a 35% reduction in hospitalization for heart failure, and a 39% reduction in progression of kidney disease compared with placebo. HbA1c difference versus placebo was modest: roughly 0.5 percentage points.

The trial enrolled about 29% women. Sex-specific subgroup analyses showed directionally consistent benefit in women, though the trial was not powered to confirm sex differences in the cardiovascular endpoint. This is a genuine evidence gap that matters for women's care decisions.

UKPDS 34 (Metformin, 1998)

UKPDS 34 enrolled 1,704 overweight patients with newly diagnosed type 2 diabetes and randomized a subgroup to metformin versus conventional dietary therapy. At 10 years, metformin produced a 32% reduction in any diabetes-related endpoint, a 42% reduction in diabetes-related death, and a 36% reduction in all-cause mortality compared with conventional therapy. These are large absolute risk reductions over a decade of follow-up. Women made up roughly 40% of the UKPDS cohort; no sex-stratified subgroup analysis for metformin's outcomes was published in the original paper.

Translating Trial Data Into Your Decision

The trials answer different questions. EMPA-REG tells you what Jardiance does when you already have a damaged cardiovascular system. UKPDS tells you what metformin does when diabetes is newly diagnosed and cardiovascular disease has not yet developed. They are not directly comparable, but together they frame a logical sequence: metformin first, Jardiance added or substituted when cardiovascular or kidney disease enters the picture.

Differences That Matter Specifically for Women

The Menstrual Cycle and Glucose Metabolism

Insulin sensitivity fluctuates across your cycle. During the luteal phase (the two weeks after ovulation), progesterone blunts insulin action, which can raise fasting and post-meal glucose by clinically meaningful amounts. Neither drug is dosed differently across the cycle in current guidelines, but women on Jardiance may notice slightly more glycosuria and potentially greater yeast infection frequency in the luteal phase when glucose spill into urine increases. This has not been formally studied but follows logically from the mechanism.

Vaginal and Urinary Tract Infections

The most clinically relevant sex-specific side effect of Jardiance is genital mycotic infection. Women have a 4 to 8 times higher anatomical risk for vulvovaginal candidiasis than men on SGLT2 inhibitors, as documented in the FDA prescribing information for empagliflozin. In clinical trials, genital infection occurred in approximately 10% of women on empagliflozin versus 1.5% on placebo. If you have recurrent yeast infections already, this is a real practical concern to discuss with your clinician before starting.

Metformin carries no specific increased infection risk. For women who already manage recurrent vulvovaginal candidiasis, that difference alone may shift the calculus.

PCOS Across Reproductive Years

Here is a life-stage framework no competitor article currently offers for this comparison:

Reproductive years with PCOS and no diabetes: Metformin is the preferred agent. It improves ovulatory function, lowers androgen levels, and may reduce first-trimester miscarriage risk in some PCOS populations, per ASRM guidance. Jardiance has no evidence base in PCOS and no fertility indication.

Reproductive years with PCOS and type 2 diabetes: Metformin remains first-line. Jardiance can be considered for cardiovascular or kidney protection only after the reproductive plan is clear, given its pregnancy contraindication.

Perimenopause with insulin resistance and/or PCOS: Metformin continues to be useful. Jardiance may be added if cardiovascular risk is elevated, HbA1c is above target, or weight is a primary concern alongside glucose control.

Post-menopause with type 2 diabetes and established CVD or CKD: This is where Jardiance earns its place most clearly, either added to metformin or as a substitute if metformin is not tolerated.

Bone Health: A Post-Menopausal Concern

SGLT2 inhibitors as a class raised bone fracture signals in some trials, though the data for empagliflozin specifically were reassuring in EMPA-REG OUTCOME. Post-menopausal women already face accelerated bone loss. The FDA label for empagliflozin does not carry a fracture warning, unlike canagliflozin. Still, if you are post-menopausal and your bone density is already low, a conversation about baseline DEXA scanning before starting an SGLT2 inhibitor is reasonable.

Metformin has a neutral to modestly protective bone effect in observational data, which is one additional reason it remains attractive in older women.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, trying to conceive, or not using reliable contraception.

Metformin in Pregnancy

Metformin is not FDA-approved for use in pregnancy, but it is widely used off-label in gestational diabetes and in women with PCOS continuing into early pregnancy. Human data from multiple cohort studies suggest it does not cause major structural birth defects. A Cochrane review of metformin in gestational diabetes found comparable maternal and neonatal outcomes versus insulin, with modest weight benefit for the mother. Metformin crosses the placenta and reaches fetal circulation, which raises long-term metabolic questions that are not yet fully answered.

For lactation: metformin is present in breast milk at low concentrations. The NIH LactMed database classifies it as generally compatible with breastfeeding, though infant monitoring for hypoglycemia is recommended.

Jardiance in Pregnancy: Avoid

Jardiance is contraindicated in the second and third trimesters of pregnancy. The FDA label states that SGLT2 inhibitors affect renal development and may cause fetal harm, as documented in the FDA safety labeling. Animal studies showed adverse renal effects. There is no adequate human trial data. No dose is considered safe in the second or third trimester.

If you are of reproductive age and starting Jardiance, you need reliable contraception. If you become pregnant while taking Jardiance, discontinue it immediately and contact your clinician.

For lactation: animal data show empagliflozin in milk. Human lactation data are absent. Avoid Jardiance while breastfeeding.

Contraception Requirements Summary

| Situation | Metformin | Jardiance | |---|---|---| | Trying to conceive | Can continue, discuss with clinician | Discontinue before conception attempt | | Pregnant (1st trimester) | Off-label use possible under supervision | Discontinue immediately | | Pregnant (2nd/3rd trimester) | Continued use in GDM is common | Contraindicated | | Breastfeeding | Generally compatible | Avoid | | Reliable contraception required? | No | Yes, if of reproductive age |

Who Should Consider Switching and in Which Direction?

Switching between these drugs is common in clinical practice. The direction and the reason matter.

Switching From Metformin to Jardiance

The most common clinical reason is adding cardiovascular or kidney protection that metformin cannot provide. Current ADA Standards of Care recommend considering an SGLT2 inhibitor independently of HbA1c when a person with type 2 diabetes has established heart failure, chronic kidney disease with eGFR above 20, or atherosclerotic cardiovascular disease. In those settings, Jardiance is often added to metformin rather than substituted for it.

Pure substitution (stopping metformin, starting Jardiance) makes sense when metformin is not tolerated due to gastrointestinal side effects, or when kidney function drops to a range where metformin must be stopped (eGFR below 30 mL/min/1.73m2 requires stopping metformin; Jardiance requires its own eGFR threshold checks per indication).

When switching, there is no required washout. You can stop metformin one day and start Jardiance the next, but monitor HbA1c at 3 months to confirm glucose control is maintained, since Jardiance's glucose-lowering effect is weaker than metformin's at equivalent baseline HbA1c.

Switching From Jardiance to Metformin

This happens less often but has clear scenarios: pregnancy planning, recurrent yeast infections that are affecting quality of life, cost barriers, or loss of insurance coverage. Jardiance costs roughly $500 to $600 per month without insurance. Generic metformin costs under $10.

When stopping Jardiance, glucose can rise within days because the drug's glucose-lowering effect disappears quickly, with a half-life of approximately 12 hours. Starting metformin at the same time prevents a gap in control. Begin metformin at 500 mg twice daily with food and titrate to a target of 1,500 to 2,000 mg daily over 4 to 6 weeks to minimize GI side effects.

Combining Both

Many women end up on both. The combination is supported by ADA guidelines and the two drugs complement each other mechanistically without overlapping side effect profiles in a clinically meaningful way. The combination produces additive HbA1c lowering and gives you both metformin's insulin-sensitizing effect and Jardiance's cardiorenal protection.

Side-Effect Profiles: The Practical Day-to-Day Differences

Metformin

GI symptoms are the primary tolerability problem. Up to 30% of users experience nausea, diarrhea, or abdominal cramping, particularly at initiation. Extended-release formulations reduce this significantly. Long-term use depletes vitamin B12; a study in Diabetes Care found 19% prevalence of B12 deficiency in long-term metformin users. Annual B12 monitoring is recommended if you have been on metformin for more than 4 years.

Metformin also carries a rare but serious risk of lactic acidosis, primarily when kidney function is severely impaired. With normal renal function, it is extremely safe.

Jardiance

Beyond genital mycotic infections (discussed above), Jardiance carries a risk of diabetic ketoacidosis (DKA) that can occur even with near-normal blood glucose, termed euglycemic DKA. This is a rare but dangerous complication. You should temporarily hold Jardiance before any major surgery, prolonged fasting, or serious illness.

Volume depletion and postural hypotension can occur, particularly in older women or those on diuretics. Jardiance also causes an increase in urine output that some women find bothersome, especially at night.

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported with SGLT2 inhibitors. This is exceedingly rare but the FDA issued a warning in 2018. Seek immediate care for any perineal pain, swelling, or fever while on Jardiance.

Who This Is Right For and Who Should Be Cautious

Metformin Is the Right Starting Point If You:

• Have newly diagnosed type 2 diabetes or prediabetes and no cardiovascular or kidney complications
• Have PCOS with insulin resistance, with or without type 2 diabetes
• Are in your reproductive years and may become pregnant
• Need an affordable, well-tolerated oral medication
• Are perimenopausal and managing insulin resistance without established CVD

Jardiance Deserves Serious Consideration If You:

• Have type 2 diabetes plus established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease (eGFR 20 to 45 range specifically for kidney indication)
• Are post-menopausal with elevated cardiovascular risk and HbA1c above target despite metformin
• Need modest blood pressure and weight reduction alongside glucose control
• Cannot tolerate metformin due to persistent GI side effects

Use Caution or Avoid If You:

• Are pregnant or trying to conceive (Jardiance is contraindicated; metformin requires individualized discussion)
• Have eGFR below 30 (metformin must be stopped; Jardiance's glucose-lowering indication also has eGFR limits)
• Have recurrent vulvovaginal candidiasis (Jardiance will likely worsen frequency)
• Have a history of recurrent UTIs (SGLT2 inhibitors may contribute, though the magnitude of risk for uncomplicated UTI is debated)

Cost, Access, and the Real-World Barrier

The cost difference between these drugs is not trivial. Metformin generic is universally affordable. Jardiance without insurance can cost $500 to $600 monthly, placing it out of reach for many women without employer-sponsored coverage or patient assistance programs. AstraZeneca and Boehringer Ingelheim offer a savings card program that can reduce out-of-pocket costs to around $10 monthly for commercially insured patients, but this does not apply to Medicare or Medicaid.

If cost is a barrier to Jardiance and your cardiovascular or kidney risk justifies it, ask your clinician about other SGLT2 inhibitors where generic versions may become available sooner, or about dapagliflozin (Farxiga), which has equivalent cardiorenal trial data in some populations.

A Note on the Evidence Gap for Women

Women were underrepresented in both landmark trials cited here. EMPA-REG OUTCOME was 29% female. UKPDS 34 was approximately 40% female. No sex-stratified analysis of cardiovascular mortality in EMPA-REG was powered to detect differences specifically in women. The cardiovascular benefit in women is directionally consistent but not independently confirmed.

This matters because women present with heart disease differently, develop type 2 diabetes at a lower BMI than men on average, and have different patterns of diabetic kidney disease progression. Until sex-stratified trials are run, the cardiorenal benefit of Jardiance in women is appropriately described as extrapolated from mixed-sex trial data, not directly confirmed in women alone. Honest practice requires saying that plainly.